Facebook icon Twitter icon Forward icon

CRO OUTSOURCING REQUESTS

Buyers looking for CRO Providers: 

In vitro model for diabetic nephropathy
We are looking for an in vitro model to test which of our substances may inhibit the high glucose induced activation or toxicity in kidney cells. MORE

Functional bioassay for cell-mediated tumor lysis formate
We are looking for an experienced laboratory that has lysing assay formats established. The assay is developed to be used as characterization assay of a monoclonal antibody. MORE

Characterization of antibody with respect to its potential to induce CRS (cytokine release syndrome)
We develop a novel mAb and look for an experienced laboratory that has worked on characterization of CRS, especially also on assays allowing prediction of in-vivo behaviour MORE

Bioassay for release of DS and DP
We are looking for an experienced laboratory that has the GMP-authorization for potency assays for biologicals with binding formate. The assay shall be an ELISA MORE

Seeking CRO able to do in vitro studies with human monocytes/macrophages, examination of drug uptake and cytokine release
Looking for a CRO to measure the uptake of drug candidates by human monocytes/macrophages (or Kupffer cells if available). FACS would be the best method, the potential to examine cells with confocal fluorescence microscopy would be an advantage. MORE

Binding assay service (RTK neurotrophin receptor)
We are looking for a provider that could perform binding assays. We have a drug candidate that we suppose to interact with RTK neurotrophin receptors. MORE

.............................................................

CRO OUTSOURCING NEWS, MAY 4th 2012

PRA to be sole CRO provider for Amgen’s Phase III biosimilar trials
Source: www.pharmatimes.com
After taking a stake in the emerging biosimilars market last December through a partnership with Watson Pharmaceuticals, Amgen has announced an exclusive agreement with clinical research organisation (CRO) PRA to conduct Phase III biosimilar trials. MORE

More information on biosimilar providers? Find here

Study: Drug and device trials vary in size and quality
Source: www.reuters.com
In an analysis of over 40,000 clinical trials registered in a government database, researchers found that many of those studies - looking at the effects of drugs, devices or behavioral interventions - were small and of inconsistent quality. MORE

More inormation on clinical trial providers? Find here

CROs Urge for Modernization of Clinical Trials
Source: www.pharmtech.com
Clinical research organizations see reform in clinical-trial process, including the establishment of chief innovation officer at FDA. The Association of Clinical Research Organizations (ACRO) testified before Congress last month to provide FDA with a number of suggestions to improve the drug-development process, MORE

List of worldwide CROs? Find here

Clinical Trial Approval Process In Brazil — Clearing The Roadblocks To International Studies
Source: http://www.lifescienceleader.com
The regulation of clinical research in Brazil started at the national level in 1996 with the publication of Resolution 196 from the National Health Council (CNS, which is a Portuguese acronym). MORE

More information on Brazilian providers for clinical trials? Find here